Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Advances in Brief

Survivin-ΔEx3 and Survivin-2B: Two Novel Splice Variants of the Apoptosis Inhibitor Survivin with Different Antiapoptotic Properties

Csaba Mahotka, Michael Wenzel, Erik Springer, Helmut E. Gabbert and Claus D. Gerharz
Csaba Mahotka
Institute of Pathology, Heinrich Heine University, D-40225 Duesseldorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Wenzel
Institute of Pathology, Heinrich Heine University, D-40225 Duesseldorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik Springer
Institute of Pathology, Heinrich Heine University, D-40225 Duesseldorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helmut E. Gabbert
Institute of Pathology, Heinrich Heine University, D-40225 Duesseldorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claus D. Gerharz
Institute of Pathology, Heinrich Heine University, D-40225 Duesseldorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published December 1999
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Expression of different survivin isoforms in human RCC cell lines. a, Northern blot hybridization revealed survivin expression in all RCC cell lines, irrespective of their histological subtypes (clear cell, chromophilic, and chromophobe types of RCC). Of note, a band of 1.3 kb indicated EPR-1 expression in clearCa-6. b, RT-PCR confirmed the results of Northern analysis showing survivin expression in all RCC cell lines as well as two additional fragments different in length from the survivin band. c, sequence analysis of the RT-PCR amplification products identified three different transcripts: The survivin transcript with four exons, survivin-2B with an additional exon (exon 2B) inserted between the exons 2 and 3, and survivin-ΔEx3, showing a loss of exon 3 as well as a frame shift with extension of the reading frame into the open reading frame of the 3′ untranslated region (arrows, PCR primer positions; flags, SD and SA sites; black boxes, the novel exon 2B; shaded boxes, the frame shift in exon 4 and the coding part of the former 3′ untranslated region). d, S1 analysis of the survivin-ΔEx3 transcript revealed the protected fragments of regular survivin (40 nucleotides) and alternatively spliced (80 nucleotides) survivin-ΔEx3 transcripts.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Analysis of potential SD and SA sites between exon 2 and 3. a, computer-aided analysis of SD/SA sites was performed on the survivin genomic sequence to confirm the data obtained from RT-PCR and DNA sequencing. *, positions of potential SD and SA sites that correspond to the SD and SA sites used in the newly discovered survivin-2B splice variant. As a result, a part of the intron between exon 2 and 3 is retained as a cryptic exon, termed exon 2B (see Fig. 1c <$REFLINK> ). SD and SA sites were analyzed with the Signal program of the PC/Gene Package Ver. 6.60, according to the algorithm developed by Staden (13) . b, comparison of the SA and SD sites of exon 2B with the consensus sequences for SA and SD sites.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Differential alterations of protein domains in the novel survivin splice variants. a, protein sequences were analyzed with the Prosite program of the PC/Gene package (21) . The BIR domain, which is known to be responsible for inhibition of certain caspases, was found to be modified in both alternative splice variants of survivin by computer analysis. Survivin-2B has acquired additional 23 amino acids encoded by the cryptic exon 2B. The novel domain introduces a potential N-glycosylation site as well as two potential N-myristoylation sites. Skipping of exon 3 in survivin-ΔEx3 results in a frame shift that causes a new COOH-terminal sequence with a potential N-myristoylation site. BIR′, modified BIR; PKC, protein kinase C phosphorylation site; N-Myr, N-myristoylation site; N-Glyc, N-glycosylation site; CK2, casein kinase 2 phosphorylation site; cAMP, cyclic AMP-dependent kinase phosphorylation site. b, multiple alignment, using Clustal W (22) and enhanced with Boxshade, of amino acid sequences of the three survivin variants. Darker shading is of residues that are highly conserved; lighter shading is of less well-conserved residues, and residues that are not shaded are not conserved.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Differential antiapoptotic potential of the novel survivin splice variants. a, coding sequences of survivin and its two splice variants were ligated into the expression vector pEGFP-N3 and transfected into the human hepatoma cell line HepG2. Cell death was induced in transient transfectants by exposure to methotrexate (100 μg/ml). Survivin-ΔEx3 transfectants exhibited cell survival frequencies closely corresponding to that of survivin transfectants. In contrast, survivin-2B transfectants showed a marked reduction of cell survival. The transfection efficiency was ≥50% in all transfection experiments. The percentage of transfected cells was determined by microscopic evaluation of β-galactosidase expressing cells. Data are the means of at least three independent experiments; bars, SD. Statistical analysis was performed with Dunnett’s test. Of note, corresponding results were obtained using untagged pcDNA3.1-survivin/survivin-ΔEx3/survivin-2B constructs (data not shown). b, immunoblot analysis with both anti-GFP and anti-survivin antibodies revealed stable and comparable levels of expression for the indicated survivin variants in HepG2 transfectants. Of note, binding of anti-GFP antibody is independent of the survivin component of the fusion protein. Additional survivin-2B bands detected by the anti-GFP antibody might indicate posttranslational modifications of this survivin variant. The polyclonal anti-survivin antibody, which was generated against “regular” survivin, detected survivin splice variants with less intensities, as evident from comparison with α-tubulin controls.

PreviousNext
Back to top
December 1999
Volume 59, Issue 24
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Survivin-ΔEx3 and Survivin-2B: Two Novel Splice Variants of the Apoptosis Inhibitor Survivin with Different Antiapoptotic Properties
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Survivin-ΔEx3 and Survivin-2B: Two Novel Splice Variants of the Apoptosis Inhibitor Survivin with Different Antiapoptotic Properties
Csaba Mahotka, Michael Wenzel, Erik Springer, Helmut E. Gabbert and Claus D. Gerharz
Cancer Res December 15 1999 (59) (24) 6097-6102;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Survivin-ΔEx3 and Survivin-2B: Two Novel Splice Variants of the Apoptosis Inhibitor Survivin with Different Antiapoptotic Properties
Csaba Mahotka, Michael Wenzel, Erik Springer, Helmut E. Gabbert and Claus D. Gerharz
Cancer Res December 15 1999 (59) (24) 6097-6102;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
  • 2-Arachidonoylglycerol
  • Recombinant Listeria Vaccines Containing PEST Sequences Are Potent Immune Adjuvants for the Tumor-Associated Antigen Human Papillomavirus-16 E7
Show more Advances in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement